Letermovir

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

EQS-News: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

Retrieved on: 
Thursday, July 6, 2023
MSD, HSV, Letermovir, Aciclovir, EAP, Therapy, Cytomegalovirus, Diabetes, Infection, ADV, Eye, Cancer, Breakthrough therapy, Research, DSM-IV codes, RNA, Life expectancy, HSCT, US, EKC, Radiation, AIDS, Patient, System Infected: Backdoor VBS Dunihi, CMV, Nightfall and Other Stories, CFO, Pritelivir, Merck, BKV, Merck & Co., Immunodeficiency, BK virus, Market Access Program, BK, Vaccine, Fine chemical, Pharmaceutical industry

AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.

Key Points: 
  • AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.
  • With AiCuris’ enhanced focus on development and commercialization of anti-infectives for immunocompromised individuals, the Company will discontinue research activities outside of this strategic scope.
  • Larry Edwards, CEO of AiCuris Anti-infective Cures AG, said: “Immunocompromised patients develop severe, partially life-threatening disease from infections that are typically well controlled in immune competent individuals.
  • Highly prevalent latent virus infections such as CMV, HSV and BKV can cause severe complications in immunocompromised patients for example, after transplantations.

Royalty Pharma Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 9, 2023
Asthma, Share repurchase, BioCryst Pharmaceuticals, Cohort, DPP, GAAP, Letermovir, Acquisition, Patient, Risk, Cystic fibrosis, Ageing, Ionis Pharmaceuticals, Psychiatry, Vertex, Cardiovascular disease, Aplastic anemia, Gilead, Bronchoconstriction, Growth, FDA, Calcitonin, Net, Pressure, Migraine, Psychosis, Schizophrenia, HER2, Cabozantinib, Leuprorelin, Psoriasis, Cytokinetics, Astellas Pharma, Progression-free survival, RCC, LVEF, Calendar, Exelixis, COVID, AstraZeneca, Sale, EBITDA, HCM, PureTech Health, Breast cancer, Generic drug, Bank, Video game, Pharmaceutical industry, Music, Bookkeeping, Ionis, Natalizumab, Sacituzumab govitecan, Ibrutinib, Salbutamol/budesonide, Elexacaftor/tezacaftor/ivacaftor, KarXT, Adjustment, Pfizer

As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.

Key Points: 
  • As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
  • Drivers of royalty receipts in the first quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • Royalty Pharma will also receive 25% of Ionis’ mid-teens to low-20% royalty on net sales of pelacarsen, resulting in a mid-single digit royalty to Royalty Pharma.

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

Retrieved on: 
Saturday, December 10, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Post, Hospital, Society, Disease, GVHD, EST, Infrastructure as code, Patient, COVID-19, Human polyomavirus 2, University of Kansas Medical Center, EBV, Valganciclovir, HC, Risk, Cytomegalovirus, Virus, City, Infection, Immunodeficiency, BK, JC, Lymphocytopenia, Degenerative disease, BK virus, Polymerase chain reaction, University, Letermovir, Blood, ELISpot, Antigen, Webcast, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCT, Death, PCR, BKV, CMV, Cytokine release syndrome, ASH, ADV, Annual report, JCV, European Medicines Agency, Division, FDA, Hemorrhagic cystitis, Safety, Biomarker, Vaccine, Pharmaceutical industry, Viremia

Biomarker data demonstrated the persistence of posoleucel and association between expansion of functional virus-specific T cells (VSTs) and viral control.

Key Points: 
  • Biomarker data demonstrated the persistence of posoleucel and association between expansion of functional virus-specific T cells (VSTs) and viral control.
  • These data were highlighted in an oral presentation ( Abstract 362 ) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans today.
  • Allogeneic hematopoietic cell transplant recipients are highly vulnerable to potentially devastating viral infections, particularly in the first 100-180 days post-transplant.
  • We are excited to see the durability of posoleucel efficacy and safety in this final data set from the Phase 2 multi-virus prevention study, which reinforces the preliminary data previously reported.

DGAP-News: AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022

Retrieved on: 
Tuesday, April 12, 2022
MSD, Drug of last resort, Company, Therapy, Pandemic, Virus, Hepatitis B virus, BK virus, Absence, AMR, DFU, Immune system, HCMV, CEO, Bacteria, Bone marrow, CMV, Research, BK, Program, Biofilm, Conference, Letermovir, RNA, Achievement, Severe acute respiratory syndrome coronavirus 2, BKV, AMPS, Immunodeficiency, POC, Artificial intelligence, Industry, Sepsis, German Future Prize, HSV, Transplant, SAAP, HBV, Infection, Patient, Pharmaceutical industry, Vaccine, Antibiotics, Science, EU, Technology, Bayer

AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022, a corporate innovation accelerator initiative at BIOCOM AMR Conference 2022

Key Points: 
  • AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022, a corporate innovation accelerator initiative at BIOCOM AMR Conference 2022
    Wuppertal, Germany, April 08, 2022 - AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the first winner of the AiCuris AiCubator initiative in 2022, the second year of the company's accelerator program.
  • "We are excited to welcome the first winner of the AiCubator Resident Status in 2022," said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG.
  • "Outstanding and novel approaches are needed to face today's healthcare threats and combat antimicrobial resistance and complex infections.
  • The AiCubator program was launched to find and promote exactly those projects - projects that bear the promise of an innovative drug based on exciting new scientific approaches."

DGAP-News: AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

Retrieved on: 
Wednesday, February 9, 2022
MSD, ASO, Cytomegalovirus, LUMC, RNA, Department, BK, BK virus, Leiden University Medical Center, Transplant, Kidney, Drug of last resort, Nephrology, HBV, Lists of diseases, Company, Holm–Bonferroni method, HSV, Cancer, Infection, Degenerative disease, Therapy, Enzyme, BKV, Program, CMV, Risk, Patient, HCMV, Survival, Hospital, RNA transfection, Severe acute respiratory syndrome coronavirus 2, CEO, Letermovir, Kidney transplantation, Hemorrhagic cystitis, Oligonucleotide, Pritelivir, Virus, Immunodeficiency, Hepatitis B virus, Bone marrow, Pharmaceutical industry, Vaccine, Hybridisation, Bayer, EU, Antisense Oligonucleotide (ASO) technology, AiCuris Anti-infective Cures AG, Hybridize Therapeutics, ANTISENSE OLIGONUCLEOTIDE (ASO) TECHNOLOGY, AICURIS ANTI-INFECTIVE CURES AG, HYBRIDIZE THERAPEUTICS

Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.

Key Points: 
  • Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.
  • Hybridize and AiCuris will collaborate in the further development of the BKV-targeting therapy until the start of clinical studies, which is expected within two years.
  • "BK virus is difficult to treat as it is not addressable using conventional approaches such as classical enzyme inhibitors.
  • Hybridize has merged these areas in its mission, focusing on helping patients overcome untreated kidney diseases with high unmet medical needs using RNA-based therapeutics.

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 11, 2021
Infectious Diseases, Biotechnology, Health, Oncology, European Medicines Agency, LinkedIn, Virus, FDA, BKV, Death, HCT, Risk, Hospital, ADV, EBV, Review, Food, Nasdaq, Private Securities Litigation Reform Act, Adult, Degenerative disease, Infection, ASH, Exposition, Blood, EST, HC, PCR, BK, Human polyomavirus 2, Valganciclovir, Safety, Hemorrhagic cystitis, Viremia, Society, Survival, VST, JCV, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Lymphocytopenia, Letermovir, City, Investor, BK virus, CMV, Twitter, Immunodeficiency, Polymerase chain reaction, Cell, Cytomegalovirus, Disease, Immune reconstitution inflammatory syndrome, Division, SEC, JC, Vaccine, Pharmaceutical industry, Posoleucel, AlloVir, POSOLEUCEL, ALLOVIR

These data were presented today at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Key Points: 
  • These data were presented today at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
  • Based on preliminary data from this Phase 2 study, the U.S. Food and Drug Administration (FDA) has agreed in principle with the companys plan to advance from this Phase 2 open-label study into a Phase 3 registrational trial.
  • The company plans to initiate this study in the first half of 2022, following FDA review of the final protocol.
  • AlloVir cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

DGAP-News: AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

Retrieved on: 
Friday, October 22, 2021
MSD, Infection, Nitric oxide, Diabetes, Biotechnology, Cell wall, HCMV, Diagnosis, Quality of life, Gram, Absence, CMV, Gram-positive bacteria, Immune system, Human, Virus, Patient, Gram-negative bacteria, Sepsis, Hepatitis B virus, Biofilm, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Osmotic pressure, HSV, Multiple organ dysfunction syndrome, Letermovir, Amputation, Company, Disease, Transplant, Veterinary medicine, CEO, Inflammation, Chemistry (relationship), German Future Prize, Bone marrow, WHO, Mortality, Hospital, Pathogenic bacteria, Prevalence, Incidence, Drug of last resort, HBV, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics, Artilysin(R) - a new class of molecules with a novel resistance-breaking mode of action and the potential to replace common antibiotics, Chronic Wounds and Diabetic Foot Infections, Lysando AG, AiCuris Anti-infective Cures AG, ARTILYSIN(R) - A NEW CLASS OF MOLECULES WITH A NOVEL RESISTANCE-BREAKING MODE OF ACTION AND THE POTENTIAL TO REPLACE COMMON ANTIBIOTICS, CHRONIC WOUNDS AND DIABETIC FOOT INFECTIONS, LYSANDO AG, AICURIS ANTI-INFECTIVE CURES AG

As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.

Key Points: 
  • As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.
  • Of note, in contrast to a systemic treatment, a topical formulation would also be beneficial in terms of antibiotic stewardship considerations.
  • In addition, the specificity of Artilysin(R)s ensures the preservation of the natural healthy human microbiome and impede recolonization of pathogens.
  • Bacterial infection is the likeliest single cause of delayed healing of chronic open wounds by secondary intention such as diabetic foot infections.

DGAP-News: AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Retrieved on: 
Monday, September 20, 2021
MSD, Infection, Serum, Hepatitis B, CMV, Bone marrow, Drug of last resort, Letermovir, Patient, Absence, German Future Prize, Virus, CEO, Company, Female, Disease, COVID-19, HCMV, Male, Severe acute respiratory syndrome coronavirus 2, Transplant, Hepatitis B virus, Immune system, Survival, Safety, Degenerative disease, Viral load, HBV, HSV, Vaccination, Pharmaceutical industry, Vaccine, AIC649, AiCuris Anti-infective Cures AG, AIC649, AICURIS ANTI-INFECTIVE CURES AG

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Key Points: 
  • AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections
    The issuer is solely responsible for the content of this announcement.
  • AIC649 is an inactivated parapoxvirus (iPPVO), which was previously in development for the treatment of chronic HBV infections at AiCuris.
  • With this novel therapy we aim to protect patients with SARS-CoV-2 infections to develop a more severe form of COVID-19 including respiratory failure.
  • In addition, based on promising pre-clinical findings, AIC649 could have potential as therapy against other respiratory viral infections with pandemic potential."